Sensus Healthcare (NASDAQ:SRTS) Given New $13.00 Price Target at Lake Street Capital

Sensus Healthcare (NASDAQ:SRTS) had its target price reduced by Lake Street Capital from $18.00 to $13.00 in a research note published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also recently weighed in on SRTS. HC Wainwright lifted their price target on Sensus Healthcare from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Maxim Group lifted their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Trading Down 3.3 %

Shares of SRTS opened at $4.43 on Tuesday. Sensus Healthcare has a 12-month low of $3.09 and a 12-month high of $9.33. The business’s 50 day moving average is $6.08 and its 200 day moving average is $6.66. The company has a market capitalization of $73.07 million, a PE ratio of 11.08 and a beta of 1.28.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Equities research analysts predict that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

A number of large investors have recently made changes to their positions in SRTS. JPMorgan Chase & Co. acquired a new stake in shares of Sensus Healthcare in the 4th quarter valued at about $27,000. Truvestments Capital LLC purchased a new stake in Sensus Healthcare during the 3rd quarter valued at approximately $32,000. Barclays PLC purchased a new stake in Sensus Healthcare during the 4th quarter valued at approximately $35,000. BNP Paribas Financial Markets purchased a new stake in Sensus Healthcare during the 4th quarter valued at approximately $47,000. Finally, IFP Advisors Inc purchased a new stake in Sensus Healthcare during the 4th quarter valued at approximately $95,000. 25.30% of the stock is owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.